Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil(TM))

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 45-50

  Skubitz, Keith M ^a,b,c   Skubitz, Amy P N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; LIPOSOME;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEIOMYOSARCOMA; LOW BACK PAIN; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CELL ADHESION; DOXORUBICIN; DRUG CARRIERS; DYSPNEA; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPHILS; POLYETHYLENE GLYCOLS;

EID: 0031886983     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00005     Document Type: Article

References (23)

1. Gabizon A, Berenholz Y, Bialer M. Prolongation of circulation time of doxoruhicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharmac Res 1993; 10: 703-8.
2. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55-3.
3. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-2.
4. Huang SK, Mahew E, Gilani S. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774-81.
5. Vaage J, Barbera-Guillem E, Abra R, Huant A, Working P. Tissue distributions and therapeutic effects of intravenous free and liposomal doxorubicin against human prostatic carcinoma xenografts. Cancer 1994; 73: 1478-84.
6. Northfelt DW. Stealth liposomal doxorubicin (SLD) delivers more doxorubicin (DOX) to AIDS-Kaposi's sarcoma (AIDS-KS) lesions than to normal skin. Proc Am Soc Clin Oncol 1994; 13: 51 (abstr).
7. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653-9.
8. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-5.
9. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunoruhicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcom. J Clin Oncol 1996; 14: 2353-4.
10. Working PK, Newman MS, Carter JL, Kerl RE, Kiorpes A. Comparative target organ toxicity of free and liposome-encapsulated doxorubicin in rats. Toxicologist 1994; 14: 217.
11. Newman MS, Yarrington J, Sullivan T, Working PK. Comparative cardiotoxicity after repeated DOX-SL administration in rabbits. Toxocologist 1994; 15: 70.
12. Madhavan S, Northfelt DW. Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 1995; 87: 1556-7.
13. Toren M, Goffinet JA, Kaplow LS. Pulmonary bed sequestration of neutrophil during hemodialysis. Blood 1970; 36: 337-0.
14. Brubaker LH, Nolph KD. Mechanisms of recovery from neutropenia induced by hemodialysis. Blood 1971; 38: 623-1.
15. Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HJ. Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879-8.
16. Craddock PR, Hammerschmidt DE, White JG, Dalmosso AP, Jacobs HS. Complement (C5a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 1977; 60: 260-4.
17. Hammerschmidt DE, White JG, Craddock PR, Jacob HJ. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest 1979; 63: 798-3.
18. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977; 296: 769-4.
19. Skubitz KM, Craddock PR. Reversal of hemodialysis granulocytopenia and pulmonary leukostasis. J Clin Invest 1981; 67: 1383-1
20. Skubitz KM, Snook RW. Monoclonal antibodies that recognize lacto-N-fucopentose III (CD15) react with the adhesion-promoting glycoprotein family (LFA-1/HMAC-1/GP 150,95) and CR1 on human neutrophils. J Immunol 1987; 139: 1631-9.
21. Vaporciyan AA, Jones ML, Ward PA. Rapid analysis of leukocyte-endothelial adhesion. J Immunol Methods 1993; 159: 93.
22. Skubitz KM, Campbell KD, Skubitz APN. CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. J Leuk Biol 1996; 60: 106-7.
23. Skubitz KM, Campbell KD, Iida J, Skubitz APN. CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. J Immunol 1996; 157: 3617-6.